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Glutathione S-transferase enzymes are active in detoxifying a wide number of endogenous and 
exogenous chemical carcinogens and subsequently, are crucial in protecting the DNA. Several studies 
show some differences in association of glutathione S-transferase M1, T1 and P1 genetic 
polymorphisms with the risk of prostate cancer in various populations. The current study was done 
with Iranian subjects to evaluate the association of the polymorphism of glutathione S-transferase 
subtypes (T, M and P) and the susceptibility of prostate cancer in Iranian patients as compared to 
controls. Blood samples were collected from 65 prostate cancer patients and 65 unrelated health 
individuals as controls from Milad hospital, Tehran, Iran. The polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP) method was used to determine the polymorphism of 
glutathione S-transferase pi (GSTP1) -313 A/G gene, while multiplex PCR method was utilized to detect 
the glutathione S-transferase teta (GSTT) 1 and glutathione S-transferase mµ (GSTM) 1 null allele. There 
was no significant association in the -313 G allele (Val) of GSTP1 gene polymorphism and prostate 
cancer risk (odds ratio 0.61, 95% confidence intervals (CI) 0.08 - 4.60, p = 0.627). Moreover, no 
relationship was found between the polymorphism of GSTT1 (odds ratio 0.66, 95% CI 0.27 - 1.62) and 
GSTM1 (odds ratio 0.54, 95% CI 0.27 - 1.08) genes and higher risk of prostate cancer among Iranian 
subjects (p > 0.05). This study showed that either GSTP1-313 G polymorphism or GSTT1 and GSTM1 
genes cannot be predisposing risk factors for prostate cancer among Iranian subjects.  
 





The phase II metabolizing enzymes such as glutathione 




*Corresponding author. E-mail: vasuphd@gmail.com. 
 
Abbreviations: GSTT, Glutathione S-transferase teta; GSTM, 
glutathione S-transferase mµ; GSTP, glutathione S-transferase 
pi; PCR, polymerase chain reaction; RFLP: restriction fragment 
length polymerase; OR: odds ratio; Cl, confidence intervals; 
PSA, prostate-specific antigen; EDTA, ethylenediamine-
tetraacetic acid. 
hydroxylase and sulphotransferase are involved in deto-
xifying chemical carcinogens in the cells and sub-
sequently protect DNA from damage (D’Errico et al., 
1996). The GST genes encode enzymes which catalyze 
the conjugation of electrophonic compound to glutathione 
(Hayes and Pulford, 1995). The vital role of these enzymes 
is to protect DNA from oxidative damage since activating 
and inactivating oxidative metabolite of carcinogenic 
com-pound is associated with causing prostate cancer 
(Ryberg et al., 1997). Among the subtypes of glutathione 
S-transferase, the null allele of glutathione S-transferase 





Table 1.  Primer sequences used in PCR for GSTT1, GSTM1 and 
GSTP1 genes.  
 
























and the glutathione S-transferase pi (GSTP) 1-313 A/G 
substitution have been most investigated in many popu-
lations with conflicting results (Ali-Osman et al., 1997). 
The GSTP1-313 A/G single nucleotide polymer-phism 
leads to an amino-acid variation of isoleu-cine/valine at 
codon 105 in the protein. The substitution of valine amino 
acid decreases the enzyme activity. Also, the null allele of 
GSTT1 and GSTM1 genes is caused by lack of enzyme 
activity (Srivastava et al., 2004). 
The increased evidences show that polymorphism of 
glutathione S-transferase genes can be associated with 
the risk of developing some types of cancer as these 
polymorphisms have been investigated in association 
with lung, bladder, colon (Ketterer et al., 1992), oral (Nair 
et al., 1992; Buch et al., 2002) and prostate cancers 
(Pemble et al., 1994; Steinhoff et al., 2000; Nakazato et 
al., 2003; Dekant and Vamvakas, 1993). Regarding prostate 
cancer, the conflicting results among different studies 
have shown a significant association in some populations 
(Steinhoff et al., 2000; Nakazato et al., 2003; Dekant and 
Vamvakas, 1993), whereas there was no association in 
others (Pemble et al., 1994; Medeiros et al., 2004; Kote-
Jarai et al., 2001). 
Nowadays, prostate cancer has become the second 
leading cause of cancer related mortality diagnosed in 
men worldwide (Mittal et al., 2004). The latest global 
estimation shows that the incidence of prostate cancer in 
Asian countries is 2.3–9.8 cases in 100,000 persons/year 
(Hsing et al., 2000). The incidence of prostate cancer in 
Iran is 5.1 in 100,000 persons/year (Safarinejad, 2006). 
The most significant factor of developing prostate cancer 
is age. The older someone is, the greater the risk (Ewis 
et al., 2002). It is quite rare that men less than 40 years 
old are at risk of developing this disease. As the affect of 
both genetic and environmental factors cannot be ignored 
in higher risk of prostate cancer, these factors seem to 
influence the metabolism of carcinogens (Rebbeck et al., 
1999). Evidences show that genetic alterations are stron-
ger than any other factor and play a major role in prostate 
cancer etiology (Mayer et al., 1999); however, some 
environmental factors such as diet and life style might 
also be a key to switch the disease.  Previous reviews 
suggest   that   different  racial  and  ethnic  groups  show  




different frequencies of gene polymorphism (Ryberg et 
al., 1997; Gsur et al., 2001; Srivastava et al., 2004). In 
this study, we attempted to find out whether the gluta-
thione S-transferase genes polymorphism is associated 
with the higher risk of prostate cancer in Iranian patients. 
The A313G polymorphism of GSTP1 gene among cases 
and controls was resolved using polymerase chain reac-
tion-restriction fragment length polymorphism (PCR-
RFLP) method, while the absence/presence of the 
GSTT1 and GSTM1 gene frequencies for prostate cancer 
patients and controls were determined by multiplex-PCR. 
 
 
MATERIALS AND METHODS  
 
The study group included a total of 130 subjects comprising 65 men 
with prostate cancer and 65 healthy men. Samples were recruited 
from Milad hospital, Tehran, Iran. Informed consent was obtained 
from all participants. All patients who participated in the study were 
in advance level of cancer that had been referred to the hospital for 
treatment in 2008. The inclusion criteria for patients were between 
40 - 50 years old (43 ± 10.24) suffering from prostate cancer based 
on diagnosis by physician. For the controls, over 40 years old men 
who were healthy with a prostate-specific antigen (PSA) level below 
<2 ng/ml were recruited. The present study was approved by the 
Ethical Committee of the Faculty of Medicine, Tonekabon Islamic 
Azad University, Tonekabon, Mazandaran, Iran. 
Five millimeter of blood was collected in sterile ethylene-
diaminetetraacetic acid (EDTA) vials from both cases and controls 
in Iran. DNA was extracted using genomic DNA extraction kit 
(Bioneer, South Korea). The purity and concentration of the 
extracted DNAs were quantified by spectrophotometry, using 
biophotometer UVette (Eppendorf, Hamburg, Germany). Study on 
the A313G polymorphism of GSTP1 was done using PCR-RFLP 
method. The forward and reverse primers sequences used for 
GSTP1 gene were those described by Srivastava et al. (2004). The 
PCR was performed in a volume of 25 µl including 60 - 100 ng of 
genomic DNA, 20 pmol of each of primers (Table 1), 5 µl of i-PCR 
5X Master Mix (iDNA, Singapore) (which contain 0.1 unit/µl of Taq 
DNA polymerase, 1 mM of dNTP’s, 10% of glycerol and 7.5 mM of 
MgCl2) and 14.5 µl distilled water in each single reaction tube. For 
negative control, all materials except template DNA were added to 
a PCR tube. The PCR cycling conditions were carried out on 
iCycler (BioRad Laboratories, Hercules, California, USA). The PCR 
cycling conditions were set up as follows:  94°C for 3 min as initial 
denaturation, 94°C for 1 min, 59°C for 1 min and 72°C for 2 min for 
30 cycles, and 72°C for 10 min as final extension. The sizes of the 
multiplex PCR products were clearly resolved in 4% agarose gel 
(Bioline, London, UK). 3 - 5 µl of 100 bp DNA marker (iDNA, 
Singapore) was run in the gel each time as a reference to estimate 
the PCR products' sizes. After the gel staining by ethidium bromide 
for 20 min, the gel was viewed under the UV light using Alpha 
Imager (Alpha Innotech, San Leandro, CA). The amplified PCR 
product for GSTP1 gene was digested by Alw26I restriction enzyme 
and electrophoresed in 4% agarose gel. The presence of restriction 
site resulted in two fragments (91 and 85 bp) which determined the 
G allele, and for the heterozygous situation (A/G polymorphism) 
there were three fragments which were 176, 91 and 85 bp.  
Multiplex PCR technique was used to detect the presence or 
absence of GSTT1 and GSTM1 genes in the genomic DNA sam-
ples. The PCR forward and reverse primers sequences for both 
genes were obtained from Srivastava et al. (2004). Exon 7 of the 
CYP1A1 gene was co-amplified as positive internal control. The 
multiplex PCR was carried out in a volume of 25 µl including 60 - 
100 ng of genomic DNA, 20 pmol of each of primers (Table 1), 5 µl 
of i-PCR 5X Master Mix (iDNA, Singapore) which contain 0.1 unit/µl  






Figure 1. A313G polymorphism of GSTP1 gene in 4 case 
subjects. PCR-RFLP product was analyzed at 4% agarose gel 
electrophoresis. Lane N: Negative control; lane 1: shows that 
enzyme has two restriction site on the gene (91, 85 bp); lanes 2 
and 4: show that the enzyme has only one restriction site (176, 





of Taq DNA Polymerase, 1 mM of dNTP’s, 10% of glycerol and 7.5 
mM of MgCl2. Negative control tubes included all materials except 
template DNA. The amplifications were executed on iCycler (Bio-
Rad Laboratories, Hercules, California, USA) PCR instrument. The 
PCR cycling conditions for multiplex PCR were set up as follows:  
94°C for 3 min as initial denaturation, 94°C for 1 min, 57°C for 1 min 
and 72°C for 2 min for 30 cycles, and 72°C for 10 min as final 
extension. The sizes of the multiplex PCR products were clearly 
resolved at 2% agarose gel (Bioline, London, UK). 3 - 5 µl of DNA 
marker (iDNA, Singapore) was added at each time in the gel as a 
reference for the amplified PCR products. The positive samples for 
GSTM1 and GSTT1 genotypes yielded bands of 215 and 480 bp, 
respectively. The internal positive control (CYP1A1) PCR product 





Allelic frequencies were calculated by gene-counting method and 
the genotype distribution with Hardy-Weinberg expectations by a 
chi-squared test. Odds ratios (OR) with 95% confidence intervals 
(CI) were estimated for the effects of high risk alleles. A level of p < 
0.05 was considered statistically significant. All the statistical ana-
lysis was carried out by using the statistical package for the social 






The present study showed the relation in A313G poly-
morphism of GSTP1 gene and the presence/absence of 
GSTT1 and GSTM1 allele in Iranian prostate cancer sub-
jects. A total of one hundred and thirty Iranian subjects 





zygous and heterozygous genotype of GSTP1 gene and 
the null (homozygous deletion of the gene) versus the 
non-deleted allele (heterozygous or homozygous pre-
sence of the gene) of GSTT1 and GSTM1 genes bet-
ween the cases and controls. In A313G polymorphism of 
GSTP1 gene, the presence of the restriction site results 
in only two fragments (91 and 85 bp) which indicate the G 
allele and three fragments of 176, 91 and 85 bp that 
confirm the A/G polymorphisms. Therefore, absence of 
restriction site in only one band (176 bp) illustrate the A 
allele of GSTP1 gene.  Whereas, the DNA band for posi-
tive genotypes of GSTM1, GSTT1 and internal positive 
control corresponded to 215, 480 and 312 bp, respec-
tively. Figure 1 show that the genotypes of Ile/Val poly-
merphism were allotted on the basis of the pattern of 
bands on the gel electrophoresis using standard met-
hods. Figure 2 demonstrate the detection of GSTT1 and 
GSTM1 null allele homozygotes by sequence-specific 
amplification using CYP1A1 gene as an internal control. 
Table 2 explains the frequencies of GSTM1, GSTT1 and 
GSTP1 alleles and genotypes by case-control status and 
the association of GST genotypes with prostate cancer 
risk among Iranian subjects. In the control samples, the 
GSTP1 Ile allele was present in 58.5% in the homo-
zygous state (Ile/Ile) while the Val allele was homozygous 
(Val/Val) in 3.1%; the remaining 38.5% were hetero-
zygous (Ile/Val) and the frequency of GSTM1 null and 
GSTT1 null was 58.5 and 84.6%, respectively. Genotype 
distributions in controls were in agreement with the Hardy-
Weinberg equilibrium. In addition, among cases, the 
homozygous state (Ile/Ile) present 35.5% where the 
homozygous state for (Val/Val) was 3.1%; the other 
61.5% were heterozygous (Ile/Val).  
 
 
DISCUSSION     
 
To our knowledge, the current study is the first investi-
gation done on Iranian subjects regarding the determi-
nation of genotypic distribution of GST genes in relation 
to prostate cancer. Several studies with inconsistent out-
comes have been conducted in different populations to 
discover any association between GSTP1, GSTT1 and 
GSTM1 gene polymorphisms with the risk of prostate 
cancer. The observations of the present study concur 
with the results obtained for some populations, whereas, 
it also oppose some others. Our findings are consistent 
with that from Austrian and German populations (Gsur et 
al., 2001; Wiencke et al., 1995) which showed no asso-
ciation for GSTP1-313 A/G or G/G polymorphism in both 
Austria (OR = 0.65; 95% CI 0.38 – 1.09) and Germany 
(OR = 1.08; 95% CI 0.66 – 1.77). Results of our study al-
so concur with that reported by Gsur et al. (2001) which 
found no association between null alleles of GSTT1 and 
GSTM1 with the risk of prostate cancer in Autriche. Ano-
ther study carried out by Rebeck et al. (1997) in the USA 
suggested that the GSTM1 genotype distribution did
 
not 
significantly  differ  between  prostate cancer patients and  






Figure 2. 11 case subjects which present polymorphism of GSTT1 and GSTM1 gene. Lane M: 100 bp stands for 
DNA marker; lane N: negative control; lane 1, 2, 3, 4, 5, 7, 8, 10 and 11: show GSTM1 (215 bp) and GSTT1 (480 bp) 
for both positive genotype; lane 6: indicates GSTT1 positive genotype (480 bp) with null allele for GSTM1 (215 bp); 
lane 9: demonstrates the null allele for both GSTT1 and GSTM1 genes and a band at 312 bp corresponding to 




Table 2. The distribution as n (%) of GST genotypes among prostate cancer subjects and 
controls. 
 
Genotype Control N (%) Case N (%) P value Odds Ratio (95.0% C.I) 
GSTT1 10 (15.40) 14 (21.50) 1.0  
Null 55 (84.60) 51 (78.50) 0.368 0.66 (0.27-1.62) 
GSTM1 27 (41.50) 37 (56.90) 1.0  
Null 38 (58.50) 28 (43.10) 0.081 0.54 (0.27-1.08) 
GSTP1 I/I 25 (38.50) 40 (61.50) 0.009* 0.39 (0.19-0.79) 
 I/V 38 (58.50) 23 (35.50) 0.649 1.60 (0.21-12.09) 
V/V 2 (3.10) 2 (3.10) 0.627 0.61 (0.08- 4.60) 
 






GSTT1-1 genotypes were significantly 
more common among cases
 
than controls (adjusted OR = 
1.83; 95% CI 1.19 – 2.80).
 
On the contrary, in India, there 
was a greater risk of prostate cancer with GSTP1-313 
A/G allele. Also, an association between GSTT1 and 
GSTM1 with higher risk of prostate cancer has been 
reported in this population (Srivastava et al., 2004). More-
over, an association between GSTP1-313 A/G or G/G 
polymorphism and the null genotype of GSTM1 with a 
greater risk of prostate cancer has been shown in Japa-
nese population (Nakazato et al., 2003). Therefore, it is 
clear that the association of prostate cancer and G allele 
of GSTP1 and null genotype of GSTM1 and GSTT1 
greatly vary in different populations. Our results did not 
provide the information that the A/G genotype of GSTP1, 
null genotype of GSTT1 and GSTM1 increase the risk of 
prostate cancer in Iranian subjects, however, they sho-
wed   an   association  between  a  combination  of  these 
genes and higher risk of prostate cancer (Table 3). The 
GSTs genes are involved in detoxification of carcinogenic 
electrophiles and toxic compounds such as industrial 
chemicals, tobacco products and drugs by conjugating 
with glutathione (Vander-Gulden et al., 1992). As in the 
null genotype of GSTT1 and GSTM1, there are inactive 
forms of the GSTs enzymes, thus deto-xification of 
activated carcinogen is reduced, and it might be followed 
by progression to develop any type of cancer 
(Guengerich et al., 1995). The GSTP1-313 A/G poly-
morphism at the nucleotide level leads to an amino-acid 
variation of isoleucine/valine at codon 105 in the protein. 
Valine amino-acid substitution results in decreased enzyme 
activity (Srivastava et al., 2004). Many studies have 
shown that GSTs are important for maintaining cellular 
genome (DNA) from damage, and their absence may re-
sult in cancer susceptibility (Ketterer et al., 1992; 
Wiencke  et al., 1995). Prostate cancer is a multi-factorial 




Table 3. The distribution of GST genotypes in the patients with prostate cancer and controls. 
 
Genotype (Triple) Controls N (%) Cases N (%) P value OR (95%CI) 
M1 &T1(+/+)&P1(I/I) 13 (20.0) 2 (18.5) 0.824 0.91 (0.38-2.17) 
M1(-/-),T1(-/-)&P1(I/VorV/V) 2 (3.1) 4 (6.2) 0.567 2.03 (0.18-22.98) 
M1(-/-), T1(-/-)&P1(I/I) 2 (3.1) 3 (4.6) 0.650 1.52 (0.25-9.44) 
M1(+/+), T1(-/-)&P1(I/I) 2 (3.1) 4 (6.2) 0.412 2.07 (0.36-11.69) 
M1(+/+),T1(-/-),P1(I/VorV/V) 4 (6.2) 3 (4.6) 0.699 0.74 (0.16-3.44) 
M1(-/-), T1(+/+)&P1(I/I) 8 (12.3) 1 (32.3) 0.008* 3.40 (1.38-8.40) 
M1(-/),T1(+/+),P1(I/VorV/V) 15 (23.1) 9 (13.8) 0.254 0.59 (0.23-1.47) 
M1&T1(+/+)&P1(I/Vor V/V) 19 (29.2) 9 (13.8) 0.036 0.39 (0.16-0.94) 
  
*p < 0.05, M (+/-) Genotypes of GSTM1 gene, T (+/-) genotypes of GSTT1 gene, P1 (I-Isolecuine, V –Valine) 




disease influenced by complex genetic as well as 
environmental factors as noted by Kolonel et al. (2004). 
The differences in results obtained by studies on different 
populations can be attributed to their different ancestries 
which can influence their whole genome, as well as 
environmental conditions and life styles that can affect 
their level of gene expressions. Some studies have 
shown that improved nutrition, stress management tech-
niques, exercise and psycho-social support actually 
changed the expression of over 500 genes in men with 
early-stage prostate cancer (Ornish et al., 2008).  
It is worth noting that there are however, some limit-
ations to this study. The sample size is relatively small as 
compare to other genetic epidemiological studies. Also, 
this sample size cannot represent the whole Iranian 
population as there are many descents dispersed over 
the country, and it is suggested to investigate on more 
samples collected from different provinces of the country 
in a more extensive study. Moreover, the genotypic freq-
uencies of GSTP1, GSTT1 and GSTM1 gene polymer-
phisms were not demonstrated in level of expression in 
this study and we did not enter any function and mech-
anism of these polymorphisms on the clinical behavior of 
prostate cancer. Besides, we considered no environ-
mental factors interfering in comparing between cases 





Based on this study, there is no association between 
GSTP1, GSTT1 and GSTM1 gene polymorphisms with 
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